In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer · 2026
Read In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses by Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13398611.txt.
Description
Farhan Ul Haq and co-authors model how gene fusions change drug response in a rare lung cancer driven by ROS1 rearrangements. Their 2026 study edits patient-derived cell lines with CRISPR to carry three resistance variants seen in clinics: G2032R, L2026M and S1986Y. Resistance to ROS1-blocking drugs is a growing problem, and patient-based lab models were scarce.
Two cell lines carrying different ROS1 fusions answered five kinase drugs unevenly, matching the pattern seen in patients. The G2032R variant blunted entrectinib and lorlatinib in particular, with docking and motion simulations explaining the clash at atomic level. Fusion identity, not just mutation, shapes which drug still works, a distinction the authors say treatment plans should respect.
Catalog record
| CREATOR | Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 66331 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |